Full-Time

Senior Applied Research Scientist

Oncology

Truveta

Truveta

201-500 employees

Healthcare data platform for researchers

Compensation Overview

$158k - $175k/yr

+ Incentive pay + Stock options

No H1B Sponsorship

Seattle, WA, USA

Hybrid

Hybrid role; in-person Planning Week required for two weeks per year.

Category
Biology & Biotech (2)
,
Required Skills
Python
R
biostatistics
Requirements
  • MD or PhD in Epidemiology, HEOR, Biostatistics, or a related field.
  • Expertise in Applied Methods: Extensive experience with statistical and econometric methods for analyzing complex real-world data, including approaches for causal inference, handling incomplete data, modeling longitudinal or time-to-event outcomes, and working with structured or hierarchical data.
  • Statistical Programming: 5+ years of hands-on experience with statistical programming in R and/or Python, with experience executing analysis plans intended for publication, particularly within the health sciences.
  • Scientific publication: 5+ years of experience developing research publications, including peer-reviewed manuscripts and conference abstracts, including handling peer review.
  • Cross-functional Collaboration: 3+ years of experience partnering with cross-functional teams and effectively communicating research findings and needs to non-technical stakeholders.
  • Team-Oriented and Results-Driven: Proven ability to work within cross-functional teams to deliver research under tight deadlines.
  • Presentation & Communication: Demonstrated ability to present complex research findings to both scientific and non-scientific audiences, adapting messaging and depth to the needs of clinicians, researchers, executives, media, and lay stakeholders.
Responsibilities
  • Proactively initiate and drive applied research studies focused on oncology, from ideation through peer-review publication.
  • Apply appropriate and rigorous methods for observational data studies, such as causal inference methods, missing data approaches, survival analysis, longitudinal data analysis, and time series analysis.
  • Write, review, and maintain code (R or Python) to process, wrangle, and analyze data, identifying problems, devising solutions, and creating methodologies that drive data insights and best practices.
  • Be accountable to agreed upon timelines for delivering research studies, working to communicate and manage dependencies.
  • Proactively manage several projects simultaneously to maximize impact and efficiency of your work.
  • Work collaboratively with internal and external stakeholders, including engineering, product, clinical informatics, and communications.
  • Represent researcher input by providing feedback on the development of research solutions that enable clinicians and researchers to address real-world healthcare challenges.
Desired Qualifications
  • Thought leadership: Experience writing and/or speaking on real-world evidence, epidemiology, biostatistics, or related areas.
  • Communication for lay audiences: Experience translating research findings for lay audiences.
  • Scientific communication: Experience presenting research to both scientific and non-scientific audiences, tailoring complexity and interpretation for diverse stakeholders.
  • Familiarity with EHR data models or clinical terminology: Understanding of oncology-relevant EHR data models, staging systems, tumor markers, treatment classes, and clinical vocabularies (ICD-10, SNOMED, LOINC, RxNorm).
  • Ability to learn quickly: Demonstrated capacity to rapidly absorb new methods, tools, and domain knowledge in a fast-paced environment.

Truveta provides a data platform, Truveta Studio, that lets researchers access patient-level health data from a network of hospitals and clinics. The platform aggregates daily-updated, compliant data and offers analytics tools, with researchers paying only for the data and analytics they use. It differentiates itself with a large, diverse dataset across all 50 states, transparent usage-based pricing, and built-in analytics for science and AI training in healthcare. The goal is to improve patient care and safety by enabling faster, data‑driven research and the development of medical AI.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$515M

Headquarters

Seattle, Washington

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Truveta raised $320 million in 2025, achieving unicorn status and climbing to No. 7 on GeekWire 200.
  • Johnathan Lancaster joined as President and CSO on January 26, 2026, strengthening oncology leadership.
  • Erik Wexler appointed to Board on March 31, 2026, deepening ties with founding member Providence.

What critics are saying

  • Century Health poaches clients with faster EHR analytics, undercutting Truveta in 6-12 months.
  • Google DeepMind's AlphaFold 4 bypasses Truveta data for drug discovery since March 30, 2026.
  • OpenAI's GPT-5o generates evidence from synthetic data, obsoleting Truveta's dataset in 6-12 months.

What makes Truveta unique

  • Truveta aggregates daily-updated EHR data from 30 health systems covering 18% of U.S. clinical care.
  • Truveta Intelligence queries live data from 130 million patients, unlike tools summarizing published research.
  • Truveta Genome Project sequences exomes of tens of millions, integrating with EHRs 10x larger than UK Biobank.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Truveta who can refer or advise you

Benefits

Competitive Compensation

Comprehensive Benefits

401(k)

Professional Development

Work/Life Autonomy

Flexible Time Off

Generous Parental Leave

Team Activities

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
GlobeNewswire
Mar 31st, 2026
Truveta deepens health system leadership with appointment of Erik Wexler to Board of Directors.

Truveta deepens health system leadership with appointment of Erik Wexler to Board of Directors. Providence President and CEO brings extensive experience advancing innovation, operations, and patient-centered care at scale. 31 mars 2026 09h00 HE | Source: Truveta BELLEVUE, Wash., March 31, 2026 (GLOBE NEWSWIRE) - Grounded in its mission of Saving Lives with Data, Truveta today announced the appointment of Erik Wexler, President and CEO of Providence, to its Board of Directors, representing Providence - one of Truveta's founding health system members. Wexler succeeds Rod Hochman, MD, former President and CEO of Providence, who has served as Truveta Board Chair since 2024 and played a foundational role in the company's formation and early growth. His appointment ensures continued leadership and partnership from Providence as Truveta expands its impact across healthcare, life sciences, government, and research. This announcement follows Truveta's recent Board leadership transition, including the appointment of Robin Damschroder, FACHE, as Chair of the Board of Directors, reflecting the company's continued focus on health system-led governance and long-term value creation. "Erik is a respected leader with a deep commitment to improving health and advancing innovation across care delivery," said Terry Myerson, CEO and Co-founder of Truveta. "His experience leading one of the nation's largest health systems, combined with a clear focus on patients and communities, will be invaluable as Truveta continues to grow and deliver on its mission of Saving Lives with Data." Wexler brings extensive experience in health system leadership, operations, and strategy, with a track record of driving performance, expanding access to care, and advancing digital and data-driven transformation. As President and CEO of Providence, he leads a comprehensive health system serving communities across the western United States. "I'm honored to join the Truveta Board and represent Providence in this important work," said Wexler. "Truveta's unique model - bringing health systems, life sciences, government, and academia together to improve care - has the potential to transform how we care for all patients. I look forward to contributing to this mission and helping ensure we continue to deliver meaningful impact for the communities we serve." Wexler's appointment reflects Truveta's continued commitment to health-system-led governance and strong alignment with its member organizations as it advances trusted, regulatory-grade evidence and accelerates innovation in clinical research. About Truveta Truveta provides unprecedented real-world data and real-time intelligence, powered by a dataset built with and owned by U.S. health systems united in a mission of Saving Lives with Data. Together, we power breakthrough discoveries, accelerate regulatory-grade evidence, and improve patient care.

The Associated Press
Jan 26th, 2026
Truveta appoints Johnathan Lancaster as president and chief scientific officer

Truveta has appointed Johnathan Lancaster, MD, PhD as President and Chief Scientific Officer. Lancaster brings over 20 years of experience in oncology and scientific leadership across academic medicine, healthcare and life sciences. He joins from Regeneron Pharmaceuticals, where he served as Senior Vice President and Head of Global Medical Affairs. Previously, he was Global Chief Medical Officer at Myriad Genetics and spent over a decade at Moffitt Cancer Center in various leadership roles, including Chair of Women's Oncology. Lancaster will lead Truveta's scientific strategy and ecosystem partnerships as the company advances its real-world evidence platform. He has authored more than 100 peer-reviewed publications and holds eight US patents in cancer detection and therapeutics. Truveta is a real-world intelligence company built with and owned by US health systems.

Truveta
Jan 26th, 2026
Truveta deepens oncology and scientific leadership with appointment of Johnathan Lancaster, MD, PhD as President and Chief Scientific Officer

Truveta deepens oncology and scientific leadership with appointment of Johnathan lancaster, MD, PhD as President and Chief Scientific Officer. Veteran physician - scientist brings decades of experience advancing oncology and genomics research across industry and academia. BELLEVUE, Wash. - January 26, 2026 - Truveta today announced the appointment of Johnathan M. Lancaster, MD, PhD as President and Chief Scientific Officer, deepening the company's scientific leadership as it advances real-world evidence to transform healthcare. Dr. Lancaster brings more than two decades of scientific and oncology leadership across academic medicine, healthcare, and life sciences. He will lead Truveta's scientific strategy and ecosystem partnerships - helping shape the company's next phase of growth as it builds the definitive intelligence platform for healthcare - delivering genomic-enabled, regulatory-grade evidence and AI-powered insights to advance patient care, clinical research, and public health. "Johnathan's extraordinary experience - spanning oncology, molecular genetics, healthcare, and life science innovation makes him uniquely suited to help lead Truveta into its next chapter," said Terry Myerson, Truveta's CEO and co-founder. "He shares our deep belief that better evidence is what ultimately changes care, especially for clinicians and patients who today still wait too long for answers. His leadership will help us unite science, medicine, and technology. That is Saving Lives with Data." "Truveta's focus has always been to turn data into intelligence that transforms healthcare," said Jay Nanduri, Truveta's Chief Technology Officer and co-founder of Truveta. "We've learned that the most durable innovation happens when technologists and clinicians build together. By uniting Johnathan's deep scientific and healthcare expertise with our technology and AI capabilities, Truveta is positioned to help accelerate discoveries that directly improve patient care." Ryan Ahern, MD, MPH, Truveta's Chief Medical Officer and co-founder, added, "Our customers and partners know how deeply we care about the quality, integrity, and purpose of our data. I'm excited to welcome Johnathan - as his credibility in academic medicine and passion for innovation in oncology and precision healthcare align perfectly with our mission. As a physician, I've learned that evidence only matters if it arrives in time to change a decision. I look forward to collaborating with him as we expand our reach and continue helping our partners advance science and improve patient outcomes." "I'm honored to join Truveta at such a pivotal time," said Dr. Lancaster. "The team has earned the trust of health systems, life sciences partners, and regulators by delivering real-world evidence with rigor and integrity. As a physician who has spent years sitting with patients and families navigating cancer decisions, I've learned how urgently better evidence is needed. As we now bring de-identified genomic data together with clinical data at unprecedented scale, we have the opportunity to build something lasting - the definitive real-time intelligence platform for healthcare, a platform that accelerates discovery, informs clinical and regulatory decisions, improves outcomes for patients, and ultimately transforms healthcare globally." Dr. Lancaster joins Truveta from Regeneron Pharmaceuticals, where he served as Senior Vice President and Head of Global Medical Affairs. Previously, he was Global Chief Medical Officer at Myriad Genetics and earlier spent more than a decade at Moffitt Cancer Center, as a gynecologic oncologist, translational researcher, Chair of Women's Oncology, Deputy Physician-in-Chief, and President of the Moffitt Medical Group Corporation. A pioneer in cancer genomics and personalized medicine, Dr. Lancaster trained in obstetrics and gynecology at the University of Cambridge and Duke University, where he also completed a fellowship in gynecologic oncology. He has authored more than 100 peer-reviewed publications, is an inventor on eight US patents in cancer detection and therapeutics, and has lectured on precision medicine around the world. About Truveta Saving Lives with Data starts with better evidence. Truveta is a real-world intelligence company unlocking breakthrough discoveries and transforming medicine with unprecedented data and predictive AI. Built with and owned by U.S. health systems, Truveta uniquely delivers regulatory-grade evidence and real-time insights used across clinical care, research, and public health.

Truveta
May 6th, 2025
Top 5 takeaways from Truveta Symposium 2025

This week Truveta Inc. gathered with leaders across healthcare, public health, and life sciences at the 3rd annual Truveta Symposium.

GeekWire
Mar 14th, 2025
Truveta Hits Unicorn Status with $320M

The 2025 GeekWire Awards, presented by Astound Business Solutions, features the Deal of the Year category with finalists Jama Software, Lexion, Smartsheet, Stoke Space, and Truveta. Truveta reached unicorn status with a $320 million funding round, valuing it at $1 billion. The awards recognize impactful deals in the Pacific Northwest, with winners announced on April 30. Community voting is open until March 23.